🌿 RehabNest - MAT Information Reference
rehabnest.rxtoolspro.com | For informational use - consult your doctor for medical decisions
💊
Free ResourceEvidence-BasedFDA-Approved
MAT Information Tool
Medication-assisted treatment is the most effective treatment available for opioid use disorder, reducing overdose mortality by 50-60%. This tool covers every FDA-approved addiction medication, how each works, who it helps, and how to access it.
What MAT is: Medication-Assisted Treatment (MAT) combines FDA-approved medications with counselling and behavioural therapies to treat substance use disorders. It's not "replacing one addiction with another." It's evidence-based medical treatment endorsed by the WHO, SAMHSA, CDC, and every major medical body. MAT reduces overdose risk, improves treatment retention, and saves lives.
💊 Buprenorphine (Suboxone, Subutex, Sublocade)
FDA-approved for Opioid Use Disorder (OUD). The most widely prescribed MAT medication in the US.
50-60%Overdose mortality reduction
Any GPCan now prescribe (no waiver)
Partial agonistMechanism of action
How it works
Partial opioid agonist, activates opioid receptors but with a ceiling effect that prevents the high and reduces overdose risk.
Reduces cravings and withdrawal symptoms without producing euphoria at therapeutic doses.
Blocks the effects of other opioids, reducing the appeal of relapse.
Suboxone combines buprenorphine with naloxone to deter injection misuse.
Who it helps
People with opioid use disorder (heroin, fentanyl, prescription opioids).
Can be started in emergency departments, primary care, and OUD treatment programmes.
Safe for people with chronic pain who also have OUD.
Available during pregnancy, reduces neonatal complications vs untreated OUD.
Formulations
Sublingual film/tablet (Suboxone, generic), daily dose taken under the tongue.
6-month implant (Probuphine), for stable patients.
Access
Any licensed physician can now prescribe without a special waiver (2023 regulatory change).
Covered by Medicaid, Medicare, and most private insurance.
SAMHSA Treatment Locator (findtreatment.gov) finds providers near you.
Telehealth prescribing now available in most states.
Key fact: Buprenorphine reduces the risk of opioid overdose death by 50-60%. People on buprenorphine are significantly more likely to remain in treatment, less likely to use illicit opioids, and less likely to contract HIV or Hepatitis C. It is the most effective treatment available for opioid use disorder.
⚗️ Methadone
The oldest and most studied MAT medication. Highly effective for severe opioid use disorder. Dispensed through federally certified OTPs.
50-60%Overdose mortality reduction
DailyDispensing (initially)
Full agonistMechanism of action
How it works
Long-acting full opioid agonist, eliminates withdrawal and cravings without producing euphoria at therapeutic doses.
Half-life of 24-36 hours provides stable coverage with once-daily dosing.
Cross-tolerance blocks the effects of other opioids.
Decades of research make it the most evidence-supported MAT for severe OUD.
Who it helps
People with severe, long-term opioid use disorder for whom other treatments have failed.
People who need a highly supervised, structured treatment environment.
Safe and preferred during pregnancy (reduces neonatal abstinence syndrome risk vs untreated use).
People with chronic pain co-occurring with OUD.
Access and structure
Dispensed only through federally certified Opioid Treatment Programmes (OTPs).
Covered by Medicaid, Medicare, and most insurance.
SAMHSA OTP locator at dpt.samhsa.gov finds certified clinics near you.
Important considerations
Requires careful dose titration, risk of overdose if dose is too high, especially early in treatment.
Interaction risk with benzodiazepines, alcohol, and other CNS depressants.
QT prolongation risk, cardiac monitoring may be needed at higher doses.
Daily clinic structure creates accountability but requires significant time commitment.
🛡️ Naltrexone (Vivitrol, ReVia)
FDA-approved for both opioid and alcohol use disorder. An opioid antagonist, blocks the rewarding effects of opioids and reduces alcohol cravings.
Opioids + AlcoholApproved for both
No opioidNon-addictive, no controlled status
AntagonistMechanism of action
How it works
Pure opioid antagonist, blocks opioid receptors completely, preventing opioids from producing any effect.
For alcohol: reduces the rewarding effects of alcohol and the craving intensity.
No opioid activity, not addictive, not a controlled substance.
Monthly injectable (Vivitrol) removes the adherence barrier of daily pills.
Who it helps
People with OUD who are fully detoxed (opioid-free for 7-10 days minimum before starting).
People with alcohol use disorder who want to reduce craving intensity.
People who can't access OTP clinics for methadone or prefer a non-opioid approach.
People with job or professional requirements that prohibit opioid medications.
Critical warnings
Naltrexone precipitates severe withdrawal if started before opioids are fully cleared. Minimum 7 days opioid-free (10-14 days for long-acting opioids).
Tolerance resets completely. If someone uses opioids while on naltrexone and tries to overcome the block, the dose needed can cause overdose after the naltrexone wears off.
Liver toxicity possible at high doses, liver function should be monitored.
Access
Any physician can prescribe. Not a controlled substance, no special waiver needed.
Oral naltrexone (ReVia, generic) is inexpensive and widely available.
Injectable Vivitrol (monthly shot) costs significantly more but improves adherence.
Covered by most insurance, Medicaid, and Medicare Part D.
💉 Naloxone (Narcan, Kloxxado)
Opioid overdose reversal medication. Not a treatment medication, it's an emergency intervention. Every person at risk of opioid overdose should have it.
MinutesTime to overdose reversal
OTCNo prescription needed
AntagonistMechanism of action
How it works
Rapidly displaces opioids from receptors, reversing overdose within 2-5 minutes.
Effect lasts 30-90 minutes, shorter than most opioids. Repeat dosing may be needed.
Has no effect on people without opioids in their system. Safe to give if unsure.
Does not treat addiction, it reverses an acute overdose event.
Who should have it
Anyone with opioid use disorder or in recovery from opioids.
Family members and close contacts of anyone who uses opioids.
Anyone who uses any street drug (due to fentanyl contamination of all supplies).
Anyone prescribed high-dose opioids for chronic pain.
FDA-approved for alcohol use disorder. Reduces the dysphoria and discomfort of early sobriety, making it easier to maintain abstinence.
Alcohol onlyIndication
Non-addictiveNo abuse potential
3x dailyDosing schedule
How it works
Modulates glutamate and GABA neurotransmitter systems disrupted by chronic alcohol use.
Reduces the protracted withdrawal symptoms, anxiety, restlessness, and dysphoria, that drive relapse in early sobriety.
Doesn't produce euphoria or have abuse potential.
Works best in people who are abstinent at treatment start.
Access and notes
Prescribed by any physician. Not a controlled substance.
Requires kidney function monitoring, not suitable for significant renal impairment.
Three times daily dosing can be a compliance barrier. Pill organisers or reminders help.
Often used with naltrexone for enhanced effect in alcohol use disorder.
⚠️ Disulfiram (Antabuse)
FDA-approved for alcohol use disorder. Creates a severe adverse reaction when alcohol is consumed, acting as a deterrent.
Alcohol onlyIndication
DeterrentMechanism type
Daily pillDosing
How it works
Blocks the enzyme that metabolises acetaldehyde (a toxic alcohol breakdown product).
Drinking alcohol causes flushing, nausea, vomiting, rapid heart rate, and severe discomfort within 10-30 minutes.
Acts as a behavioural deterrent rather than treating the underlying craving.
Most effective when taken under supervised conditions (a family member or clinician witnesses the dose).
Important warnings
Avoid all alcohol-containing products, mouthwash, cooking wine, some sauces, cough syrups.
Reaction can be severe and medically dangerous at high alcohol doses.
Not suitable for people with severe heart disease, liver disease, or psychosis.
Effectiveness depends heavily on motivation, people determined to drink can simply stop taking it.
🚬 Varenicline (Chantix) & NRT
FDA-approved for nicotine/tobacco use disorder. Varenicline is the most effective single medication for smoking cessation. Nicotine replacement therapy (NRT) is also highly effective.
Most effective single medication for smoking cessation, tripling quit rates vs placebo.
Requires prescription. 12-week course, can be extended.
Monitor for mood changes, though FDA removed its black box warning after further evidence review.
Nicotine Replacement Therapy (NRT)
Patch, gum, lozenge, inhaler, and nasal spray, all FDA-approved OTC or prescription.
Provides controlled nicotine delivery to reduce withdrawal without the harms of smoking.
Combination NRT (patch + gum) more effective than single form.
Available without prescription. Relatively low cost. Widely accessible.
🚫 Myths vs facts about MAT
❌ Myth
"MAT is just trading one addiction for another."
✅ Fact
MAT is medical treatment. Buprenorphine and methadone produce physical dependence (as many medications do) but not addiction, they reduce craving, support function, and prevent death. By the same logic, insulin is "trading one dependency for another."
❌ Myth
"You're not really sober if you're on MAT."
✅ Fact
SAMHSA, AA General Service, and the medical community define recovery as including MAT. Many 12-step programmes now explicitly welcome MAT patients. Recovery is about quality of life, function, and freedom from addiction, not absence of all medications.
❌ Myth
"You have to want to quit to make MAT work."
✅ Fact
MAT works regardless of baseline motivation. Research shows that reducing withdrawal and craving through medication often increases motivation over time. People who start MAT primarily to avoid withdrawal frequently develop genuine recovery orientation.
❌ Myth
"MAT should only be used short-term."
✅ Fact
There is no clinical evidence supporting arbitrary time limits on MAT. Opioid use disorder is a chronic brain condition. Long-term MAT produces better outcomes than short-term use followed by discontinuation. Duration should be based on individual clinical need, not programme ideology.
🌱 How to access MAT
1
Call SAMHSA: 1-800-662-4357
Free, confidential, 24/7. They will refer you to local MAT providers who accept your insurance or offer sliding-scale fees. The single best starting point.
2
Search findtreatment.gov
SAMHSA's online treatment locator. Search by zip code, substance, medication type, and payment method. Updated regularly with verified providers.
3
Ask your primary care doctor
Since 2023, any licensed physician can prescribe buprenorphine without a special waiver. Your family doctor may be able to start treatment immediately. Many are now doing so.
4
Try telehealth MAT
Services like Bicycle Health, Ophelia, and ARIA offer buprenorphine treatment via video appointment, often with same-day start. Good option if local providers have waiting lists.
5
Know your insurance rights
The Mental Health Parity and Addiction Equity Act requires most insurers to cover MAT at the same level as other medical treatments. If your insurance denies coverage, file an appeal or contact your state insurance commissioner.
The evidence is settled, MAT saves lives
Medication-assisted treatment for opioid use disorder reduces overdose mortality by 50-60%. That's not a small effect. It's larger than the mortality benefit of most medications in all of medicine. A 2021 study published in JAMA Psychiatry found that buprenorphine and methadone treatment reduced all-cause mortality by 59% and 76% respectively in people with OUD.
The evidence for MAT in alcohol use disorder is nearly as strong. Naltrexone reduces heavy drinking days and prevents relapse to heavy drinking in people who are motivated to reduce or stop. Acamprosate improves abstinence rates. Combined, these medications represent a significant clinical advance over willpower alone.
Despite this evidence, less than 20% of people with opioid use disorder in the US receive MAT. The barriers are stigma, access, and misinformation, not clinical appropriateness. This tool exists to address the information barrier. The Withdrawal Timeline Tool and Harm Reduction Guide provide additional context for people considering treatment options.
For families: If your loved one is on MAT, they're receiving the most effective treatment available for their condition. Supporting their treatment adherence, not pressuring them to stop medication, is the most helpful thing you can do. See the Family Support Guide for more on supporting someone in treatment.
Frequently asked questions
This is a clinical decision that depends on your substance use history, living situation, co-occurring conditions, insurance, and personal preferences. Buprenorphine is the first-line recommendation for most people with OUD due to its safety profile and office-based prescribing. Methadone is preferred for people with severe OUD who haven't responded to other treatments. Naltrexone is preferred for people who are fully detoxed and want a non-opioid option. Discuss the options with a physician who can assess your individual situation.
Yes. AA's General Service Office has stated that MAT is a medical decision between a patient and their doctor and doesn't affect AA membership or working the steps. Many NA groups are now explicitly MAT-welcoming. Some groups maintain outdated attitudes, if you encounter stigma, find a different group. SMART Recovery is fully supportive of MAT and may be a better fit for some people on medication. Don't let meeting culture override medical treatment.
There is no clinically justified time limit for MAT. Duration should be determined by individual need, clinical response, and personal goals, not by programme ideology or arbitrary cutoffs. Research shows that longer treatment duration produces better outcomes. Stopping MAT early significantly increases overdose risk. If and when you decide to taper, do so slowly and with medical supervision, not abruptly.
Several options exist. Medicaid covers MAT in all 50 states. SAMHSA's helpline (1-800-662-4357) can identify state-funded programmes. Generic buprenorphine is significantly cheaper than brand-name Suboxone. Patient assistance programmes from manufacturers provide free medication for qualifying patients. Federally Qualified Health Centres (FQHCs) provide sliding-scale care. Cost should not be a barrier, call SAMHSA first to navigate your options.